Study design and rationale of "Synergistic Effect of Combination Therapy with Cilostazol and ProbUcol on Plaque Stabilization and Lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial

BACKGROUND: Probucol, a cholesterol-lowering agent that paradoxically also lowers high-density lipoprotein cholesterol has been shown to prevent progression of atherosclerosis. The antiplatelet agent cilostazol, which has diverse antiatherogenic properties, has also been shown to reduce restenosis i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Young-Guk, Kim, Byeong-Keuk, Lee, Byoung Kwon, Kang, Woong Chol, Choi, Seung Hyuk, Kim, Sang Wook, Lee, Jong Ho, Lee, Myoungsook, Honda, Yasuhiro, Fitzerald, Peter J, Shim, Won-Heum
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033833/
https://www.ncbi.nlm.nih.gov/pubmed/21226953
http://dx.doi.org/10.1186/1745-6215-12-10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033833/
https://www.ncbi.nlm.nih.gov/pubmed/21226953
http://dx.doi.org/10.1186/1745-6215-12-10

Ejemplares similares